What D5991 means

D5991 covers a vesiculobullous disease medicament carrier. "D" is dental, "59" places it in the maxillofacial prosthetics area, and "91" is this medicament carrier. 'Vesiculobullous' means characterized by vesicles (small blisters) and bullae (larger blisters) — a family of mucosal diseases. A 'medicament carrier' is a custom tray that CARRIES/holds medication against the tissue. So D5991 is the custom tray delivering topical medication to treat blistering/erosive oral mucosal disease.

So it's a custom tray that holds medicine against inflamed gums and mouth tissue — treating chronic blistering diseases.

Vesiculobullous diseases of the mouth are chronic, often autoimmune conditions where the mucosa blisters and erodes: pemphigus vulgaris — an autoimmune disease causing fragile blisters that rupture into painful erosions (the mouth is often the first/worst site); mucous membrane (cicatricial) pemphigoid — autoimmune blistering that can cause 'desquamative gingivitis' (raw, peeling, painful gums) and scarring; and erosive lichen planus — an inflammatory condition producing painful erosions and desquamative gingivitis. These cause chronic pain, difficulty eating/brushing, and reduced quality of life; the mainstay of treatment is often TOPICAL corticosteroids (and sometimes other agents) applied to the affected mucosa. But the mouth is a hard place to keep topical medication in contact: saliva washes it away, the tongue wipes it off, and rinses/ointments have brief, uneven contact — so the drug often can't act long enough where it's needed (especially on the gingiva). A vesiculobullous medicament carrier solves this delivery problem: a custom tray (like a soft, close-fitting gingival tray) made from the patient's model holds the prescribed medication gel against the affected gums/tissues, keeping it in prolonged, even, targeted contact for the application period. This dramatically improves topical drug delivery to the gingiva — better disease control, often with LOWER systemic exposure than pills (an advantage, since systemic steroids/immunosuppressants carry significant side effects). The carrier is used per the managing clinician's protocol (often oral medicine/oral pathology specialists), typically alongside broader medical management of the disease. It's a targeted drug-delivery device, not a restorative prosthesis. Coverage is medical/dental, by report. This code is in the maxillofacial prosthetics area. Documentation supports the claim.

When it's typically used

D5991 is reported for a vesiculobullous disease medicament carrier — a custom tray holding topical medication (usually corticosteroid gel) in prolonged, targeted contact with the gums/oral mucosa to treat vesiculobullous diseases (pemphigus vulgaris, mucous membrane pemphigoid, erosive lichen planus). It improves topical drug delivery to the gingiva — better control with lower systemic exposure than pills — used within the managing clinician's treatment plan.

How much does D5991 cost?

A vesiculobullous medicament carrier's cost reflects a custom-fitted tray from the patient's model. Sample fee-schedule values (e.g., some state Medicaid programs) place it around the $80 level as the base allowance, varying by region — modest relative to the disease control it enables. The prescription medication is a separate ongoing cost. It's a medical/dental benefit, by report. Verify coverage with the relevant plan.

Is D5991 covered by insurance?

Coverage for a vesiculobullous medicament carrier is usually a medical/dental benefit (delivering topical therapy for a chronic mucosal disease), determined by report. Documentation of the diagnosis (often biopsy-confirmed pemphigus/pemphigoid/lichen planus), the topical-therapy plan, and the carrier's delivery role supports the claim. It's typically part of oral medicine/specialist management. Verifying coverage helps.

What vesiculobullous diseases do to the mouth

Autoimmune blistering erodes the mucosa, and understanding this clarifies the code.

Understanding the diseases clarifies D5991. Vesiculobullous diseases are chronic conditions — often autoimmune — where the oral lining blisters and breaks down: pemphigus vulgaris — the immune system attacks the 'glue' between mucosal cells; blisters form and rupture easily into raw, painful erosions; the mouth is frequently the first and most severely affected site, and it's a serious systemic disease; mucous membrane (cicatricial) pemphigoid — autoimmune blistering at a deeper layer; in the mouth it often shows as desquamative gingivitis — gums that are red, raw, peeling, and painful; it can scar (including in the eyes — a reason it needs proper medical management); erosive lichen planus — a chronic inflammatory disease producing lacy white patches WITH painful erosions and desquamative gingivitis; and the shared burden — all cause chronic oral pain, make eating and toothbrushing miserable, and grind down quality of life; flares and remissions come and go, demanding long-term management.

These are real diseases needing real diagnosis (often biopsy, sometimes immunofluorescence) and medical care — not simple 'mouth sores.' Topical anti-inflammatory therapy (usually corticosteroids) to the affected mucosa is central to controlling the oral component. So vesiculobullous diseases chronically blister and erode the mouth, needing sustained topical therapy. Understanding this helps patients see that vesiculobullous diseases are chronic conditions (often autoimmune) where the oral lining blisters and breaks down — pemphigus vulgaris (the immune system attacking the 'glue' between mucosal cells, blisters forming and rupturing easily into raw painful erosions, the mouth frequently the first and most severely affected site, a serious systemic disease), mucous membrane/cicatricial pemphigoid (autoimmune blistering at a deeper layer, in the mouth often showing as desquamative gingivitis/gums that are red, raw, peeling, and painful, able to scar including in the eyes — a reason it needs proper medical management), erosive lichen planus (a chronic inflammatory disease producing lacy white patches WITH painful erosions and desquamative gingivitis), and the shared burden (all causing chronic oral pain, making eating and toothbrushing miserable, and grinding down quality of life, flares and remissions coming and going, demanding long-term management) — these being real diseases needing real diagnosis (often biopsy, sometimes immunofluorescence) and medical care, not simple 'mouth sores,' topical anti-inflammatory therapy (usually corticosteroids) to the affected mucosa being central to controlling the oral component.

The topical delivery problem

The mouth washes medicine away, and understanding this clarifies the device.

Understanding the delivery challenge clarifies D5991. Topical steroids work only where and as long as they CONTACT the tissue — and the mouth conspires against that: the washout problem — saliva continuously bathes and dilutes; the tongue and cheeks wipe surfaces; swallowing clears the mouth; a gel dabbed on the gums may be gone in minutes, long before it can act; the gingiva especially — desquamative gingivitis affects the gums, a surface that's constantly disturbed by the tongue, lips, and eating; keeping medication on the gingiva by finger or rinse is especially hard; contact time drives effect — anti-inflammatory topical effect depends on prolonged, adequate contact; brief exposure gives weak control, tempting escalation to systemic drugs (with their bigger risks); and what the carrier fixes — a custom tray holds the medication gel against the affected gingiva/mucosa evenly and continuously for the whole application period (worn for the prescribed minutes, often once or several times daily), so the drug actually stays where the disease is, long enough to work.

This is the same principle as the fluoride carrier (D5986) — a custom tray solving 'keep an agent on the tissue long enough' — applied to disease-modifying medication instead of fluoride. So the carrier defeats the mouth's washout, delivering sustained topical therapy to the gingiva. Understanding this helps patients see that topical steroids work only where and as long as they CONTACT the tissue and the mouth conspires against that — the washout problem (saliva continuously bathing and diluting, the tongue and cheeks wiping surfaces, swallowing clearing the mouth, a gel dabbed on the gums possibly gone in minutes long before it can act), the gingiva especially (desquamative gingivitis affecting the gums, a surface constantly disturbed by the tongue, lips, and eating, keeping medication on the gingiva by finger or rinse being especially hard), contact time drives effect (anti-inflammatory topical effect depending on prolonged adequate contact, brief exposure giving weak control, tempting escalation to systemic drugs with their bigger risks), and what the carrier fixes (a custom tray holding the medication gel against the affected gingiva/mucosa evenly and continuously for the whole application period/worn for the prescribed minutes, often once or several times daily, so the drug actually staying where the disease is long enough to work) — this being the same principle as the fluoride carrier (D5986, a custom tray solving 'keep an agent on the tissue long enough') applied to disease-modifying medication instead of fluoride.

Better control with less systemic risk

Targeted topical delivery can spare the whole body, and understanding this clarifies the benefit.

Understanding the benefit clarifies D5991. The carrier's value goes beyond comfort — it can shift the whole treatment strategy toward safer ground: the systemic-drug problem — when topical therapy fails to control these diseases, clinicians often must escalate to systemic corticosteroids and immunosuppressants; these can work but carry significant risks (metabolic effects, infection risk, bone loss, and more) over the long term these chronic diseases demand; maximizing topical effect — by delivering medication effectively to the gingiva, the carrier can achieve better local control at the site — potentially controlling disease that finger-applied gel couldn't, and potentially reducing the NEED to escalate systemic doses; the exposure trade — topical delivery concentrates drug at the mucosa with relatively limited systemic absorption compared with swallowing pills; better local effect for less whole-body exposure is a favorable trade in long-term management; part of a plan — the carrier isn't a cure; it's a delivery tool within the managing clinician's strategy (diagnosis, monitoring, topical and/or systemic therapy, dental care, and watching for complications like secondary infection or, in pemphigoid, eye involvement); and the specialist context — these diseases are typically co-managed (oral medicine/oral pathology, dermatology, others); the carrier supports the topical arm of that care.

So a humble tray can meaningfully improve control while helping limit reliance on riskier systemic drugs. So the carrier improves local control and can help spare the patient heavier systemic medication. Understanding this helps patients see that the carrier's value goes beyond comfort (able to shift the whole treatment strategy toward safer ground) — the systemic-drug problem (when topical therapy fails to control these diseases clinicians often having to escalate to systemic corticosteroids and immunosuppressants, these able to work but carrying significant risks/metabolic effects, infection risk, bone loss, and more over the long term these chronic diseases demand), maximizing topical effect (by delivering medication effectively to the gingiva the carrier able to achieve better local control at the site, potentially controlling disease that finger-applied gel couldn't and potentially reducing the NEED to escalate systemic doses), the exposure trade (topical delivery concentrating drug at the mucosa with relatively limited systemic absorption compared with swallowing pills, better local effect for less whole-body exposure being a favorable trade in long-term management), part of a plan (the carrier not being a cure but a delivery tool within the managing clinician's strategy/diagnosis, monitoring, topical and/or systemic therapy, dental care, and watching for complications like secondary infection or in pemphigoid eye involvement), and the specialist context (these diseases typically co-managed/oral medicine/oral pathology, dermatology, others, the carrier supporting the topical arm of that care) — so a humble tray able to meaningfully improve control while helping limit reliance on riskier systemic drugs.

Where D5991 fits in the codes

D5991 is a medicament-delivery carrier among the maxillofacial codes, and understanding this clarifies the coding.

Understanding where D5991 sits clarifies the coding. D5991 is among the maxillofacial prosthetics codes (D5900s), in the medicament-carrier family — custom trays that deliver a therapeutic agent to oral tissue: D5991 (vesiculobullous disease medicament carrier — this code: delivers medication/steroid to blistering-erosive mucosal disease), D5986 (fluoride gel carrier — delivers fluoride to protect high-risk teeth), and the periodontal medicament carriers (deliver medication for periodontal contexts). All share one idea: a custom tray holding an agent against tissue for effective contact. They contrast with the restorative prostheses and the surgical/radiation devices in the section.

So D5991 is precisely: a vesiculobullous disease medicament carrier (the custom tray delivering topical drug to treat pemphigus/pemphigoid/erosive lichen planus). It's distinguished from the fluoride carrier (D5986 — fluoride for decay, not disease-modifying drug for mucosal disease) and from periodontal carriers by the target disease/agent. The provider codes D5991 for the vesiculobullous drug-delivery tray. So D5991 is the mucosal-disease medicament carrier in the maxillofacial codes. Understanding this helps patients see that D5991 is among the maxillofacial prosthetics codes (D5900s) in the medicament-carrier family (custom trays that deliver a therapeutic agent to oral tissue) — D5991 (vesiculobullous disease medicament carrier, this code: delivers medication/steroid to blistering-erosive mucosal disease), D5986 (fluoride gel carrier, delivers fluoride to protect high-risk teeth), and the periodontal medicament carriers (deliver medication for periodontal contexts) — all sharing one idea (a custom tray holding an agent against tissue for effective contact), contrasting with the restorative prostheses and the surgical/radiation devices in the section — so D5991 is precisely a vesiculobullous disease medicament carrier (the custom tray delivering topical drug to treat pemphigus/pemphigoid/erosive lichen planus), distinguished from the fluoride carrier (D5986, fluoride for decay not disease-modifying drug for mucosal disease) and from periodontal carriers by the target disease/agent, the provider coding D5991 for the vesiculobullous drug-delivery tray.

Frequently asked questions

What is the D5991 dental code?

It's a vesiculobullous disease medicament carrier — a custom tray that holds topical medication (usually a corticosteroid gel) against the gums and oral tissues to treat chronic blistering/erosive diseases like pemphigus vulgaris, mucous membrane pemphigoid, and erosive lichen planus. It keeps the medicine in prolonged, targeted contact with the affected tissue, far more effectively than rinses or finger-applied ointment.

What are vesiculobullous diseases?

Chronic, often autoimmune conditions where the oral lining blisters and erodes — pemphigus vulgaris (fragile blisters rupturing into painful raw areas), mucous membrane pemphigoid (blistering causing raw, peeling 'desquamative' gums, and possible scarring), and erosive lichen planus (painful erosions with lacy white patches). They cause chronic pain and make eating and brushing miserable, needing long-term medical management.

Why is a special tray needed to apply the medicine?

Because the mouth washes medication away fast — saliva dilutes it, the tongue wipes it off, swallowing clears it — so a gel dabbed on the gums may be gone in minutes. Anti-inflammatory effect needs prolonged contact. The custom tray holds the medication evenly against the affected gums for the whole application period, so the drug actually stays where the disease is, long enough to work.

Does it reduce the need for stronger drugs?

It can help. When topical therapy is delivered effectively, it can achieve better local control at the gum tissue — potentially controlling disease that finger-applied gel couldn't, and potentially reducing the need to escalate to systemic steroids or immunosuppressants (which carry significant long-term risks). Concentrating drug at the mucosa with limited whole-body exposure is a favorable trade.

How is it different from a fluoride carrier?

Same idea, different agent and target: both are custom trays that hold something against tissue for prolonged contact. The fluoride carrier (D5986) delivers fluoride to protect high-risk teeth from decay. The vesiculobullous carrier (D5991) delivers disease-modifying medication (usually a steroid) to treat blistering/erosive mucosal disease. One protects teeth; the other treats the mouth's lining.

Is it covered, and what does it cost?

It's usually a medical/dental benefit (delivering therapy for a chronic mucosal disease), by report — supported by the diagnosis (often biopsy-confirmed) and the topical-therapy plan. Sample fee schedules list a base allowance around $80 for the tray, plus the ongoing cost of prescription medication. Verify your specific coverage.

This page is an independent, plain-language explanation for general information only. It is not billing, coding, or clinical advice. For the official CDT descriptor and current-year wording, refer to the American Dental Association.